Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Home Blood Pressure Monitoring and blood pressure (BP) control
ISRCTN ISRCTN25105161
ClinicalTrials.gov identifier NCT00202137
Public title Home Blood Pressure Monitoring and blood pressure (BP) control
Scientific title
Acronym HBPM
Serial number at source NA 4882
Study hypothesis Hypertension is a common problem in Canada with a prevalence of about 15%. The goal of hypertension therapy should be to maximize blood pressure control. Home Blood Pressure Monitoring (HBPM) devices are available and many patients are using them. The role that self-monitoring of blood pressure can play in optimizing blood pressure control is unclear. We hope to clarify the role of home blood pressure monitoring in the treatment of hypertension and explore how it may affect patient and physician behaviours related to blood pressure management. This study will compare a group of hypertensive patients who use HBPM with those who do not use these devices.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Canada
Disease/condition/study domain Hypertension
Participants - inclusion criteria 1. Adults (age 18 and older) who are patients of family physicians
2. Must be diagnosed with essential hypertension but not have yet achieved target levels
Participants - exclusion criteria 1. A diagnosis of secondary hypertension
2. Pregnancy
3. Hypertension management primarily by a consultant
4. A disability that precludes use of a home blood pressure monitor
5. Enrolled in another hypertension trial
6. White coat hypertension
Anticipated start date 01/07/2002
Anticipated end date 01/11/2006
Status of trial Completed
Patient information material
Target number of participants 630
Interventions Patients in the intervention group are provided with a home blood pressure monitor that they are to use at least once a week and report the BP measurements to their physician at each follow up visit.
Primary outcome measure(s) 1. The mean daytime blood pressures on Ambulatory Blood Pressure Monitoring (ABPM)
2. The mean night-time blood pressures on ABPM
3. Achieving Blood Pressure (BP) target at end of study
4. Achieving 10% drop in the mean nighttime blood pressures
Secondary outcome measure(s) 1. Patient lifestyle changes
2. The number of visits for hypertension
3. Compliance with hypertensive medication use
4. Compliance with the intervention
5. Intensity of treatment
6. Frequency of lifestyle counselling by physician
7. Quality of Life as measured by 36-item Short Form health survey (SF-36)
Sources of funding Heart and Stroke Foundation of Ontario (Canada)
Trial website
Publications 1. 2003 protocol in http://www.ncbi.nlm.nih.gov/pubmed/14690550
2. 2005 results in http://www.ncbi.nlm.nih.gov/pubmed/15985180
Contact name Dr  Marshall  Godwin
  Address Centre for Studies in Primary Care
Dept of Family Medicine
220 Bagot Street
  City/town Kingston, Ontario
  Zip/Postcode K7L 5E9
  Country Canada
  Tel +1 613-549-4480
  Fax +1 613-544-9899
  Email godwinm@post.queensu.ca
Sponsor Heart and Stroke Foundation of Ontario (Canada)
  Address 1920 Yonge Street
4th Floor
  City/town Toronto, Ontario
  Zip/Postcode M4S 3E2
  Country Canada
  Tel +1 416 489 7100
  Fax +1 416 489 6885
  Email mail@hsf.on.ca
Date applied 14/08/2003
Last edited 18/03/2010
Date ISRCTN assigned 08/09/2003
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central